204 related articles for article (PubMed ID: 34173283)
1. A functional three-dimensional microphysiological human model of myeloma bone disease.
Visconti RJ; Kolaja K; Cottrell JA
J Bone Miner Res; 2021 Oct; 36(10):1914-1930. PubMed ID: 34173283
[TBL] [Abstract][Full Text] [Related]
2. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
Hung KC; Chang JF; Hsu YH; Hsieh CY; Wu MS; Wu MY; Chiu IJ; Syu RS; Wang TM; Wu CC; Hung LY; Zheng CM; Lu KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218086
[TBL] [Abstract][Full Text] [Related]
4. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
5. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
[TBL] [Abstract][Full Text] [Related]
7. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
8. An in vitro model for discovery of osteoclast specific biomarkers towards identification of racehorses at risk for catastrophic fractures.
Malek G; Richard H; Beauchamp G; Laverty S
Equine Vet J; 2023 May; 55(3):534-550. PubMed ID: 35616632
[TBL] [Abstract][Full Text] [Related]
9. [The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease].
Ma RJ; Yang SW; Yuan XL; Jiang L; Yang J; Wang Z; Zhang Y; Lei PC; Zhang L; Shang BJ; Cheng LN; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2032-2035. PubMed ID: 32654448
[No Abstract] [Full Text] [Related]
10. A 3D in vitro bone organ model using human progenitor cells.
Papadimitropoulos A; Scherberich A; Güven S; Theilgaard N; Crooijmans HJ; Santini F; Scheffler K; Zallone A; Martin I
Eur Cell Mater; 2011 May; 21():445-58; discussion 458. PubMed ID: 21604244
[TBL] [Abstract][Full Text] [Related]
11. Myeloma bone disease: Progress in pathogenesis.
Xi H; An R; Li L; Wang G; Tao Y; Gao L
Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181
[TBL] [Abstract][Full Text] [Related]
12. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Green AC; Lath D; Hudson K; Walkley B; Down JM; Owen R; Evans HR; Paton-Hough J; Reilly GC; Lawson MA; Chantry AD
J Bone Miner Res; 2019 Dec; 34(12):2311-2326. PubMed ID: 31442332
[TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
[TBL] [Abstract][Full Text] [Related]
14. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
15. Trabecular bone deterioration in col9a1+/- mice associated with enlarged osteoclasts adhered to collagen IX-deficient bone.
Wang CJ; Iida K; Egusa H; Hokugo A; Jewett A; Nishimura I
J Bone Miner Res; 2008 Jun; 23(6):837-49. PubMed ID: 18251701
[TBL] [Abstract][Full Text] [Related]
16. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
18. Measuring mineralised tissue formation and resorption in a human 3D osteoblast-osteoclast co-culture model.
Remmers S; Mayer D; Melke J; Ito K; Hofmann S
Eur Cell Mater; 2020 Nov; 40():189-202. PubMed ID: 33152099
[TBL] [Abstract][Full Text] [Related]
19. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
[TBL] [Abstract][Full Text] [Related]
20. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
